Effectiveness of Pedialink CEASE Module
|ClinicalTrials.gov Identifier: NCT01087177|
Recruitment Status : Completed
First Posted : March 16, 2010
Last Update Posted : March 22, 2012
The study involves the testing of a Pedialink module through parent exit interviews in one intervention practice and one control practice. Pedialink is the American Academy of Pediatrics' online home for continuous professional development. The intervention site will complete the Pedialink module and the control site will be given routine tobacco control materials.
We will measure changes in practice patterns in the two pediatric practices following the implementation of the online training. At each of these practices, the parents or guardians of children seen by the practice will be surveyed for a one week period before, and a one week period six weeks after either using the online training module (intervention) or being given routine tobacco materials (control).
A follow-up telephone survey will be given to some parents at 3-months. Those given the telephone survey are parents or guardians who smoke or parents or guardians who live with a smoker and are surveyed at the second time-point.
We hypothesize that intervention practices will have higher rates of screening for home and car no-smoking rules and higher rates of advising for home and car no-smoking rules.
|Condition or disease||Intervention/treatment||Phase|
|Tobacco Use||Other: Exposure to practice that has been trained in Pedialink CEASE||Not Applicable|
This study will involve developing an online training and dissemination system to train pediatricians to address the secondhand smoke exposure of children. We will gather pediatric staff responses to the specific components of the online training and refine this training for a range of outpatient pediatric office settings. We will test the feasibility and efficacy of implementing the online training and dissemination system within the pediatric office setting. We will also gather parental responses to specific components of the pediatric visit, which will be impacted by the online training for pediatric offices.
The following hypotheses will be tested:
H1. The following measures of physician behavior, as assessed by exit interviews, 3 month follow up telephone interviews of parents or guardians who smoke or parents or guardians who live with a smoker and chart review of 20 charts, will increase more in the intervention practice than in the control practice:
- Screening for home no-smoking rule
- Screening for car no-smoking rule
- Advising parents about the need for a strictly enforced no-smoking in the home rule
- Advising parents about the need for a strictly enforced no-smoking in the car rule.
Secondary Hypothesis H2. Compared to the control practice, the intervention practice will have a greater increase in the summary scores that measure the key processes of practice implementation shown to predict successful practice change. This implementation process will be measured by administering previously validated surveys to physicians and key practice staff before and following the implementation of the office system.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||647 participants|
|Intervention Model:||Parallel Assignment|
|Primary Purpose:||Health Services Research|
|Official Title:||Evaluating Online Clinical Office-Systems Training to Address SHS Exposure of Children|
|Study Start Date :||March 2010|
|Actual Primary Completion Date :||February 2011|
|Actual Study Completion Date :||February 2011|
Experimental: Exposure to Pedialink CEASE Trained Site
Parents at a practice where the clinicians were trained to address tobacco use through the Pedialink CEASE module.
Other: Exposure to practice that has been trained in Pedialink CEASE
Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
- Rate of home and car no smoking rules. [ Time Frame: Three months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01087177
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Jonathan P Winickoff, MD, MPH||Harvard Medical School|